Radiation Sickness

DGAP-News: Eckert & Ziegler Affiliate to Receive Multi-Million Euro Grant from the European Defense Fund for Development of Medical Countermeasures

Retrieved on: 
Thursday, August 4, 2022

The current program has the potential to advance its MCM candidate towards a marketing authorization application at the end of the four-year funding period.

Key Points: 
  • The current program has the potential to advance its MCM candidate towards a marketing authorization application at the end of the four-year funding period.
  • Beyond its potential as a medical countermeasure, the MCM portfolio has several promising clinical applications in mitigating radiation and chemotherapy-induced toxicity in nuclear medicine and (radiation) oncology.
  • About Eckert & Ziegler: Eckert & Ziegler Strahlen- und Medizintechnik AG with its 900 employees, is a leading global specialist for isotope-related applications in nuclear medicine, industry, and radiation therapy.
  • The primary manifestation of ARS is the depletion of hematopoietic stem and progenitor cells, constituting one of the major causes of mortality.

DGAP-News: Eckert & Ziegler Affiliate Receives Further NIAID Funding for Clinical Development

Retrieved on: 
Thursday, July 21, 2022

Preclinical and clinical studies have shown that Myelo001 has prophylactic and therapeutic efficacy in reducing hematopoietic symptoms caused by radiation and chemotherapy.

Key Points: 
  • Preclinical and clinical studies have shown that Myelo001 has prophylactic and therapeutic efficacy in reducing hematopoietic symptoms caused by radiation and chemotherapy.
  • Comprehensive chronic toxicology and safety studies, as well as clinical studies, have confirmed Myelo001s excellent safety profile.
  • About Eckert & Ziegler: Eckert & Ziegler Strahlen- und Medizintechnik AG with its 900 employees, is a leading global specialist for isotope-related applications in nuclear medicine, industry, and radiation therapy.
  • Eckert & Ziegler shares (ISIN DE0005659700) are listed in the SDAX index of Deutsche Brse.

2021 Report on Radiation Toxicity Drugs In Development - ResearchAndMarkets.com

Retrieved on: 
Thursday, September 16, 2021

This report provides an overview of the Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) (Toxicology) pipeline landscape.

Key Points: 
  • This report provides an overview of the Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) (Toxicology) pipeline landscape.
  • The Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) (Toxicology) pipeline guide also reviews of key players involved in therapeutic development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) and features dormant and discontinued projects.
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) (Toxicology).
  • The pipeline guide reviews latest news related to pipeline therapeutics for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) (Toxicology)

‘Historic Win’ by Children's Health Defense in Case Against FCC on Safety Guidelines for 5G and Wireless

Retrieved on: 
Monday, August 16, 2021

Washington, DC, Aug. 16, 2021 (GLOBE NEWSWIRE) -- Childrens Health Defense (CHD) won its historic case against the Federal Communications Commission (FCC), challenging the agencys decision not to review its 1996 health and safety guidelines for wireless-based technologies, including 5G.

Key Points: 
  • Washington, DC, Aug. 16, 2021 (GLOBE NEWSWIRE) -- Childrens Health Defense (CHD) won its historic case against the Federal Communications Commission (FCC), challenging the agencys decision not to review its 1996 health and safety guidelines for wireless-based technologies, including 5G.
  • The FCC guidelines test for a 30-minute exposure from a single device and consider only heat effects on tissue.
  • Addressing the courts decision, CHDs lead attorney for the case, Scott McCollough, a telecommunications and administrative law attorney, said, This is an historic win.
  • Children's Health Defense was Represented by Robert F. Kennedy, Jr., and Scott McCollough.

Cytocom, Inc. and La Jolla Institute for Immunology Announce Five-Year Research Alliance Agreement

Retrieved on: 
Thursday, August 12, 2021

Working with the La Jolla Institute, we will deeply explore the mechanisms that we believe will drive next-generation therapeutic development with our AIMS technology and bring hope to patients and their families battling serious medical conditions."

Key Points: 
  • Working with the La Jolla Institute, we will deeply explore the mechanisms that we believe will drive next-generation therapeutic development with our AIMS technology and bring hope to patients and their families battling serious medical conditions."
  • Under the terms of the research agreement, the La Jolla Institute may select up to four laboratories to participate in research.
  • Cytocom will also provide researchers at the La Jolla Institute with samples and materials.
  • Founded in 1988, La Jolla Institute for Immunology is a nonprofit, independent biomedical research institute focused on improving human health through increased understanding of the immune system.

Cytocom, Inc. Announces Participation at Liberty University's Empowering the Kingdom Through Business Conference

Retrieved on: 
Wednesday, August 11, 2021

Cytocom President and CEO, Mike K. Handley, will participate live as a featured panelist in the Healthcare Breakout session moderated by Dean Joseph Johnson on August 11, 2021.

Key Points: 
  • Cytocom President and CEO, Mike K. Handley, will participate live as a featured panelist in the Healthcare Breakout session moderated by Dean Joseph Johnson on August 11, 2021.
  • Specifically, Cytocom has several clinical-stage development programs for Crohn's disease, pancreatic cancer, COVID-19 in addition to expansion to fibromyalgia and multiple sclerosis.
  • While we believe these expectations are reasonable, such forward-looking statements are inherently subject to risks and uncertainties, many of which are beyond our control.
  • The forward-looking statements included in this press release are made only as of the date hereof.

Cytocom, Inc. to Report Second Quarter 2021 Financial Results

Retrieved on: 
Tuesday, August 10, 2021

A replay of the webcast will be archived on the website for 90 days beginning at approximately10:00 a.m.

Key Points: 
  • A replay of the webcast will be archived on the website for 90 days beginning at approximately10:00 a.m.
  • Specifically, Cytocom has several clinical-stage development programs for Crohn's disease, pancreatic cancer, COVID-19 in addition to expansion to fibromyalgia and multiple sclerosis.
  • The company's actual future results may differ materially from those discussed here for various reasons.
  • We do not undertake any obligation to update any such statements or to publicly announce the results of any revisions to any of such statements to reflect future events or developments.

Cytocom Inc. Provides Updates on Key Clinical Programs for Crohn's Disease, Hematology, Pancreatic Cancer and COVID-19

Retrieved on: 
Monday, August 9, 2021

"We are strategically focused on immune-modulating treatments designed to address anemia and neutropenia, emergent viruses, cancer, and autoimmune diseases."

Key Points: 
  • "We are strategically focused on immune-modulating treatments designed to address anemia and neutropenia, emergent viruses, cancer, and autoimmune diseases."
  • Building on our legacy Cytocom pipeline are the Cleveland BioLabs assets, specifically entolimod, an immune-stimulatory agent.
  • Cytocom is developing CYTO-401 as an adjunct to standard of care therapy to extend the duration of disease remission in patients withpancreatic cancer.
  • Specifically, Cytocom has several clinical-stage development programs for Crohn's disease, hematology, pancreatic cancer, and COVID-19 in addition to expansion to fibromyalgia and multiple sclerosis.

Cytocom Inc. Provides Update on Completed Merger with Cleveland BioLabs

Retrieved on: 
Thursday, August 5, 2021

FORT COLLINS, Colo., Aug. 5, 2021 /PRNewswire/ -- Cytocom Inc. (NASDAQ: CBLI), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today provided shareholders with an update regarding its recent merger with Cleveland BioLabs.

Key Points: 
  • FORT COLLINS, Colo., Aug. 5, 2021 /PRNewswire/ -- Cytocom Inc. (NASDAQ: CBLI), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today provided shareholders with an update regarding its recent merger with Cleveland BioLabs.
  • The all-stock transaction, first announced in October 2020, was formally completed on July 27, 2021.
  • Continental Stock Transfer & Trust is responsible for implementing the issuance of shares of public Cytocom common stock in accordance with the exchange ratio.
  • Cytocom acquired ImQuest Life Sciences in an all-stock deal, first announced on July 20, 2020, and completed on June 23, 2021.